R9Q Stock Overview
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Recce Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.13 |
| 52 Week High | AU$0.35 |
| 52 Week Low | AU$0.13 |
| Beta | 0.73 |
| 1 Month Change | 3.10% |
| 3 Month Change | -44.12% |
| 1 Year Change | -61.11% |
| 3 Year Change | -74.67% |
| 5 Year Change | -63.66% |
| Change since IPO | -58.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| R9Q | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -6.6% | 0.8% |
| 1Y | -61.1% | -27.7% | 14.6% |
Return vs Industry: R9Q underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: R9Q underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| R9Q volatility | |
|---|---|
| R9Q Average Weekly Movement | 24.0% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: R9Q's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R9Q's weekly volatility has increased from 15% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | James Graham | www.recce.com.au |
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.
Recce Pharmaceuticals Ltd Fundamentals Summary
| R9Q fundamental statistics | |
|---|---|
| Market cap | €41.60m |
| Earnings (TTM) | -€10.30m |
| Revenue (TTM) | €5.51m |
7.5x
P/S Ratio-4.0x
P/E RatioIs R9Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R9Q income statement (TTM) | |
|---|---|
| Revenue | AU$9.59m |
| Cost of Revenue | AU$10.81m |
| Gross Profit | -AU$1.22m |
| Other Expenses | AU$16.72m |
| Earnings | -AU$17.94m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.072 |
| Gross Margin | -12.69% |
| Net Profit Margin | -186.95% |
| Debt/Equity Ratio | -79.4% |
How did R9Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 09:58 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recce Pharmaceuticals Ltd is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pooya Hemami | Edison Investment Research |
| Jyoti Prakash | Edison Investment Research |
| Chris Kallos | MST Financial Services Pty Limited |